Abstract

Sildenafil citrate (SILC) is a potent phosphodiesterase-5 inhibitor used for erectile dysfunction and pulmonary hypertension. This study shows two simple, fast and alternative analytical methods for SILC determination by non-aqueous titration and by derivative ultraviolet spectrophotometry (DUS) in active pharmaceutical ingredient and/or dosage forms. The quantitation method of SILC active pharmaceutical ingredient by non-aqueous acid-base titration was developed using methanol as solvent and 0.1 mol/L of perchloric acid in acetic acid as titrant. The endpoint was potentiometrically detected. The non-aqueous titration method shows satisfactory repeatability and intermediate precision (RSD 0.70-1.09%). The neutralization reaction occurred in the stoichiometric ratio 1:1 in methanol. The determination of SILC active pharmaceutical ingredient or dosage forms by DUS was developed in the linear range from 10 to 40 µg/mL, in 0.01 mol/L HCl, using the first order zero-peak method at λ 256 nm. The DUS method shows selectivity toward tablets excipients, appropriate linearity (R2 0.9996), trueness (recovery range 98.86-99.30%), repeatability and intermediate precision in three concentration levels (RSD 1.17-1.28%; 1.29-1.71%, respectively). Therefore, the methods developed are excellent alternatives to sophisticated instrumental methods and can be easily applied in any pharmaceutical laboratory routine due to simple and fast executions.

Highlights

  • Sildenafil citrate (SILC, Figure 1) is a potent 5-fosfodiesterase (PDE-5) inhibitor with a pharmacological effect through an increase in intracellular concentration of cyclic guanosine monophosphate, a potent vasodilator

  • SILC is a compound of the pyrazolopyrimidinyl-methyl piperazine class used for erectile dysfunction treatment and for pulmonary arterial hypertension (Escribano, Jimínez, Calzada, 2005; American College of Cardiology Foundation; American Heart Association, 2009; Galiè et al, 2010, Sawatdee, Phetmung, Srichana, 2013)

  • Compounding pharmacies aim the production in a smaller scale of the different formula containing SILC, as their dispensation is commonly high due to the PDE5 inhibitor popularity

Read more

Summary

Introduction

Sildenafil citrate (SILC, Figure 1) is a potent 5-fosfodiesterase (PDE-5) inhibitor with a pharmacological effect through an increase in intracellular concentration of cyclic guanosine monophosphate (cGMP), a potent vasodilator. SILC is a compound of the pyrazolopyrimidinyl-methyl piperazine class used for erectile dysfunction treatment and for pulmonary arterial hypertension (Escribano, Jimínez, Calzada, 2005; American College of Cardiology Foundation; American Heart Association, 2009; Galiè et al, 2010, Sawatdee, Phetmung, Srichana, 2013). The trend of the number of pharmaceutical companies around the world, that will produce drugs containing SILC, is to increase. Compounding pharmacies aim the production in a smaller scale of the different formula containing SILC, as their dispensation is commonly high due to the PDE5 inhibitor popularity. In order to assure the manufacturing uniformity for the treatment of erectile dysfunction or pulmonary hypertension, as well as for quality

Objectives
Methods
Results
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call